Large TAM Takes Lead Role: Novel Tests in Specialized Markets

Our third panel, “Large TAM Takes Lead Role: Novel Tests in Specialized Markets,” featured John Aballi, President & CEO of Exagen Inc., Dorian LeBlanc., CFO of LumiraDx, Guido Baechler, CEO of Mainz Biomed, Lishan Aklog, MD, Chairman & CEO of PAVmed Inc., and Scott Powell, EVP, IR & CFO of Volition. The panel was moderated by Cantor’s Ross Osborn, CFA.

• The panelists discussed how their tests are used to catch various diseases at an early or pre-cancerous stage to give patients the best opportunity for a healthy life
• Dorian LeBlanc highlighted how Lumira aims to offer a widely used diagnostic POC system that will offer a menu of tests at a low cost while maintaining a high sensitivity
• Despite macro headwinds in 2022, the panelists walked attendees through their key achievements this year, such as establishing central laboratories, expanding commercialization activities, and receiving or making progress in receiving reimbursement for their tests. As a result, panelists held a positive tone for 2023

#Cantor #Cantorfitzgerald #Cantorhealthcare #Cantorconferenceseries #Dermatology #Opthalmology #Medtech #Diagnostic